Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2022 Publisher: AbbVie Ltd., Maidenhead, SL6 4UB, UK
Alphagan 0.2% w/v (2 mg/ml) eye drops, solution.
| Pharmaceutical Form |
|---|
|
Eye drops, solution. Clear, greenish-yellow to light greenish-yellow solution. |
One ml solution contains 2.0 mg brimonidine tartrate, equivalent to 1.3 mg of brimonidine.
Excipient with known effect: Contains benzalkonium chloride 0.05 mg/ml.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Brimonidine |
Brimonidine is an alpha2-adrenergic receptor agonist that is 1000-fold more selective for the alpha2-adrenoceptor than the alpha1-adrenoreceptor. This selectivity results in no mydriasis and the absence of vasoconstriction in microvessels associated with human retinal xenografts. |
| List of Excipients |
|---|
|
Benzalkonium chloride |
White low density polyethylene dropper bottles with a 35 microlitre tip. The cap is either a conventional polystyrene screw cap or a Compliance Cap (C-Cap).
2.5 ml, 5 ml and 10 ml bottles in packs of 1, 3 or 6. Not all pack sizes may be marketed.
AbbVie Ltd., Maidenhead, SL6 4UB, UK
PL 41042/0052
Date of first authorisation: 18 March 1997
Date of last renewal: 17 September 2006
| Drug | Countries | |
|---|---|---|
| ALPHAGAN | Austria, Australia, Brazil, Canada, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Malta, Mexico, Netherlands, New Zealand, Poland, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
